No Data
Syren Biotech: 2024 Annual Report
Syren Biotech: 2024 Annual Report Summary
Syren Biotech: First Quarter 2025 Report
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Siren Bio (688163.SH): DeepSeek has not been deployed.
Gelonghui reported on March 20 that Siron Biopharma (688163.SH) stated on the interaction platform that so far, the company has not deployed DeepSeek and will pay attention to the latest developments and applications in related fields.
Cyron Biotech: Salen Biotech: 2024 Annual Results Express Announcement
Is Shanghai Serum Bio-Technology Co., Ltd.'s (SHSE:688163) Stock On A Downtrend As A Result Of Its Poor Financials?